Q-TWiST analysis of survival benefits with brigatinib versus crizotinib in patients with anaplastic lymphoma kinase-positive non-small cell lung cancer based on results of the ALTA-1L trial

Author:

Garcia Campelo M.R.,Wan Y.,Lin H.M.ORCID,Chen T.,Shen J.,Zhang P.,Camidge D.R.

Publisher

Elsevier BV

Subject

Cancer Research,Pulmonary and Respiratory Medicine,Oncology

Reference21 articles.

1. American Cancer Society 2022, Key Statistics for Lung Cancer. https://www.cancer.org/cancer/lung-cancer/about/key-statistics.html, 2022 (accessed 18 November 2022).

2. American Society of Cancer Oncology, Lung Cancer - Non-Small Cell: Statistics. https://www.cancer.net/cancer-types/lung-cancer-non-small-cell/statistics, 2022 (accessed 2 November 2022).

3. Routine molecular profiling of patients with advanced non-small-cell lung cancer: Results of a 1-year nationwide programme of the French Cooperative Thoracic Intergroup (IFCT);Barlesi;Lancet,2016

4. S.J. Rodig, M. Mino-Kenudson, S. Dacic, B.Y. Yeap, A. Shaw, J.A. Barletta, H. Stubbs, K. Law, N. Lindeman, E. Mark, P.A. Janne, T. Lynch, B.E. Johnson, A.J. Iafrate, L.R. Chirieac, Unique clinicopathologic features characterize ALK-rearranged lung adenocarcinoma in the western population, Clin. Cancer Res. 15 (2009). https://doi.org/10.1158/1078-0432.CCR-09-0802.

5. Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines ®) for Non-Small Cell Lung Cancer V2.2023. © National Comprehensive Cancer Network, Inc. 2023. All rights reserved. Accessed April 4, 2023. To view the most recent and complete version of the guideline, go online to NCCN.org. NCCN makes no warranties of any kind whatsoever regarding their content, use or application and disclaims any responsibility for their application or use in any way.

Cited by 1 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3